Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical giant Bristol-Myers Squibb (NYS: BMY) has earned a respected four-star ranking.
With that in mind, let's take a closer look at Bristol-Myers' business and see what CAPS investors are saying about the stock right now.
New York (1887)
CEO Lamberto Andreotti
Return on Equity (Average, Past 3 Years)
$8.7 billion / $5.5 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 94% of the 1,752 members who have rated Bristol-Myers believe the stock will outperform the S&P 500 going forward.
Good numbers, good payout ratio, good debt, good cash on hand, good pipeline, good diversity of drugs, and good dividend.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Bristol-Myers may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
At the time thisarticle was published Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.